摘要
目的探究克罗恩病(CD)患者血清嗜酸性粒细胞趋化因子(CCL11)及肠脂肪酸结合蛋白(I-FABP)水平表达与疾病活动指数的相关性。方法选取2021年2月至2023年2月于上海市杨浦区中心医院就诊的98例CD患者进行研究(CD组),根据疾病活动指数(CDAI)评分将患者分为缓解期21例、轻度活动期31例、中度活动期28例和重度活动期18例,另选取同期健康者100例作为对照组,采用酶联免疫吸附法检测血清CCL11、I-FABP水平,采用Spearman法分析血清CCL11、I-FABP水平与CDAI评分的相关性,采用受试者工作特征曲线(ROC)分析血清CCL11、I-FABP水平对CD患者疾病活动度的评估价值。结果CD组患者的血清CCL11、I-FABP水平分别为(51.33±7.14)pg/mL、(64.85±11.56)ng/mL,明显高于对照组的(28.56±6.61)pg/mL、(31.38±10.35)ng/mL,差异均有统计学意义(P<0.05);缓解期、轻度、中度、重度活动期CD患者血清CCL11水平分别为(31.47±7.02)pg/mL、(45.52±7.08)pg/mL、(57.83±7.12)pg/mL、(74.41±7.43)pg/mL,I-FABP水平分别为(48.13±10.79)ng/mL、(59.97±11.32)ng/mL、(70.76±11.75)ng/mL、(83.58±12.58)ng/mL,缓解期、轻度活动期、中度活动期、重度活动期CD患者血清CCL11、I-FABP水平依次升高,差异均有统计学意义(P<0.05)。Spearman相关性分析结果显示,血清CCL11、I-FABP水平均与CDAI评分呈正相关(r=0.834、0.620,P<0.01);ROC分析结果显示,血清CCL11、I-FABP水平评估CD患者疾病活动度的AUC分别为0.882、0.889,敏感性为81.82%、80.52%,特异性为85.71%、85.71%。两者联合评估疾病活动度的AUC为0.938,显著高于单项检测(P<0.05),联合检测的敏感性和特异性为93.51%、85.71%。结论CD患者血清CCL11、I-FABP水平升高,与疾病活动指数密切相关,且两者联合评估CD患者疾病活动度具有较高效能。
Objective To investigate the correlation between the expression of serum C-C motif chemokine 11(CCL11)and intestinal fatty acid binding protein(I-FABP)levels and disease activity index in patients with Crohn's disease(CD).Methods A study was conducted on 98 CD patients who visited Shanghai Yangpu District Central Hospital from February 2021 to February 2023(CD group).According to the Crohn's Disease Activity Index(CDAI)score,CD patients were separated into 21 in remission,31 in mild activity,28 in moderate activity,and 18 in severe activity.Another 100 healthy individuals were regarded as the control group.Enzyme linked immunosorbent assay(ELISA)was applied to detect serum levels of CCL11 and I-FABP.Spearman method was applied to analyze the correlation between serum CCL11,I-FABP levels and CDAI score.Receiver operating characteristic(ROC)curve was applied to analyze the evaluation value of serum CCL11 and I-FABP levels on disease activity in CD patients.Results The serum levels of CCL11 and I-FABP in CD group were(51.33±7.14)pg/mL and(64.85±11.56)ng/mL,which were significantly higher than(28.56±6.61)pg/mL and(31.38±10.35)ng/mL in the control group(P<0.05).The serum CCL11 levels of patients with CD in remission,mild,moderate,and severe activity were(31.47±7.02)pg/mL,(45.52±7.08)pg/mL,(57.83±7.12)pg/mL,(74.41±7.43)pg/mL,respectively,and the I-FABP levels were(48.13±10.79)ng/mL,(59.97±11.32)ng/mL,(70.76±11.75)ng/mL,and(83.58±12.58)ng/mL,respectively.The serum CCL11,and I-FABP levels in CD patients during remission,mild activity,moderate activity,and severe activity increased sequentially,and the differences were statistically significant.(P<0.05).Spearman correlation analysis showed that serum CCL11 and I-FABP levels were positively correlated with CDAI score(r=0.834,P<0.001;r=0.620,P<0.001).The AUC of serum CCL11 and I-FABP levels in assessing disease activity in CD patients was 0.882 and 0.889,respectively,with the sensitivity of 81.82%and 80.52%and the specificity of 85.71%and 85.71%.The AUC of the c
作者
杨晓英
窦维嘉
庞秀峰
YANG Xiao-ying;DOU Wei-jia;PANG Xiu-feng(Department of Emergency,Shanghai Yangpu District Central Hospital,Shanghai 200090,CHINA;Department of Infectious Diseases,Shanghai Yangpu District Central Hospital,Shanghai 200090,CHINA)
出处
《海南医学》
CAS
2024年第12期1685-1689,共5页
Hainan Medical Journal
基金
中华国际医学交流基金会项目(编号:Z—2017—24—2026)。
